EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Research progress on metabolic abnormalities in myocardial hypertrophy

Xueru Liu, Yanlin Liu, Meng Huang, Fan Ouyang, Yukun Li

Frontiers in Cardiovascular Medicine · 31.07.2026 · 13

DOI: 10.3389/fcvm.2026.1912835 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 31.07.2026. Verfasst von Xueru Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial hypertrophy is initially an adaptive response to mechanical, neurohumoral, or metabolic stress, but persistent hypertrophy increases the risk of heart failure, arrhythmia, and death. Metabolic remodeling is now recognized as an early driver rather than a passive consequence of increased workload. This review aims to summarize recent advances in metabolic abnormalities in myocardial hypertrophy, focusing on pathophysiological mechanisms, biomarker implications, therapeutic opportunities, and future directions. Current evidence establishes that hypertrophic myocardium exhibits substrate inflexibility, impaired fatty acid oxidation, increased glycolysis with anaplerotic rerouting, mitochondrial calcium and quality-control defects, NAD + -sirtuin disruption, redox stress and ferroptosis, branched-chain amino acid accumulation, and ketone body adaptation. These abnormalities interact with canonical growth pathways including AMPK, mTOR, PKA, YAP, STAT3, ERR, SIRT3/SIRT5/SIRT6, and inflammatory programs. In biomarker research, metabolomics has moved from single metabolites toward integrated panels combining circulating acylcarnitines, amino acids, ketones, redox markers, and imaging-derived hypertrophy; however, interpretation remains strongly context-dependent on etiology, disease stage, sex, renal function, diabetes, and therapy. Therapeutically, phenotype-specific strategies—such as NAD + repletion, SIRT activation, BCAA catabolism modulation, and ferroptosis inhibition—are emerging but require biomarker-guided trials. Despite these advances, critical challenges remain: distinguishing adaptive compensation from maladaptive remodeling, validating tissue-to-plasma concordance, establishing longitudinal human cohorts with serial metabolomics, and developing harmonized multi-omics pipelines. By addressing these core issues, this review provides a comprehensive, clinically oriented perspective on the current state and future trajectory of metabolic research in myocardial hypertrophy, emphasizing the need for biomarker-enriched interventions before irreversible remodeling occurs.

Schlagwörter

Stichwörter der Autor:innen

biomarkersbranched-chain amino acidscardiac metabolismfatty acid oxidationglycolysisketone bodiesmetabolic remodelingmetabolomics

Autor:innen und Institutionen

  • Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
  • Shaoyang Central Hospital, Shaoyang, Hunan, China.
  • Department of Cardiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.

Zitieren

APA

Liu, X., Liu, Y., Huang, M., Ouyang, F., & Li, Y. (2026). Research progress on metabolic abnormalities in myocardial hypertrophy. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1912835

Vancouver

Liu X, Liu Y, Huang M, Ouyang F, Li Y. Research progress on metabolic abnormalities in myocardial hypertrophy. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1912835

BibTeX
@article{Liu2026,
  author = {Liu, Xueru and Liu, Yanlin and Huang, Meng and Ouyang, Fan and Li, Yukun},
  title = {Research progress on metabolic abnormalities in myocardial hypertrophy},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1912835}
}
Kostenlos starten →